UK Pharma’s Bid To Curb NHS Pricing Power Fails In Court
Executive Summary
The ABPI decides not to appeal after the High Court rejected what NHS England called 'flawed legal manoeuvres' which the judge said would ‘produce an absurd result.’
You may also be interested in...
NICE Appraisal Changes: Confusing, Contradictory & Questionable
New NICE and NHS England appraisal rules regarding timelines and price thresholds could fast-track new cost-effective drugs but then delay them from reaching patients for up to three years. The new regulations, which will come into force in April, have raised a lot of questions around methodology and impact outside of England.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.